jpad journal

AND option

OR option

Current issue

Ahead of print articles

 

TREATMENT EFFECTS OF VORTIOXETINE ON COGNITIVE FUNCTIONS IN MILD ALZHEIMER’S DISEASE PATIENTS WITH DEPRESSIVE SYMPTOMS: A 12 MONTH, OPEN-LABEL, OBSERVATIONAL STUDY

E. Cumbo, S. Cumbo, S. Torregrossa, D. Migliore

Show summaryHide summary

BACKGROUND/OBJECTIVES:depressive symptoms are common in Alzheimer’s disease(AD). Aim of the study was to investigate the efficacy of vortioxetine compared with other conventional antidepressants on cognitive functions in AD patients with depressive symptoms. DESIGN: Prospective, randomized, 12 month, parallel-group study. SETTING: All participants were evaluated on-site at Neurodegenerative Disorders Unit, ASP2 Caltanissetta(Italy). PARTICIPANTS: 108(71 female, 37 male) AD patients with depression(mean age 76.7± 4.3). INTERVENTION: Randomized subjects received vortioxetine, 15 mg/day(n=36) or other common antidepressants(n=72). MEASURES:primary outcome was change from baseline in the MMSE; secondary outcomes were change in Attentive Matrices, Raven Coloured Progressive Matrices, Digit Span, HAM-D and Cornell scale. RESULTS: Statistically significant improvement vs. controls was observed for vortioxetine on most of the cognitive tests and showed significantly baseline-to-endpoint reduction in both HAM-D and Cornell total scores.The most commonly reported adverse events were nausea and headache for votioxetine; nausea in the control group. CONCLUSIONS: Vortioxetine had a beneficial effect on cognition and mood in elderly AD patients and was safe and well tolerated.

CITATION:
E. Cumbo ; S. Cumbo ; S. Torregrossa ; D. Migliore (2019): Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer’s Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.24

Download PDFView HTML

Read more...

MACHINE LEARNING ALGORITHM HELPS IDENTIFY NONDIAGNOSED PRODROMAL ALZHEIMER’S DISEASE PATIENTS IN THE GENERAL POPULATION

O. Uspenskaya-Cadoz, C. Alamuri, L. Wang, M. Yang, S. Khinda, Y. Nigmatullina, T. Cao, N. Kayal, M. O’Keefe, C. Rubel

Show summaryHide summary

Background: Recruiting patients for clinical trials of potential therapies for Alzheimer’s disease (AD) remains a major challenge, with demand for trial participants at an all-time high. The AD treatment R&D pipeline includes around 112 agents. In the United States alone, 150 clinical trials are seeking 70,000 participants. Most people with early cognitive impairment consult primary care providers, who may lack time, diagnostic skills and awareness of local clinical trials. Machine learning and predictive analytics offer promise to boost enrollment by predicting which patients have prodromal AD, and which will go on to develop AD. Objectives: The authors set out to develop a machine learning predictive model that identifies prodromal AD patients in the general population, to aid early AD detection by primary care physicians and timely referral to expert sites for biomarker confirmation of diagnosis and clinical trial enrollment. Design: The authors use a classification machine learning algorithm to extract patterns within healthcare claims and prescription data three years prior to AD diagnosis/AD drug initiation. Setting: The study focused on subjects included within proprietary IQVIA US data assets (claims and prescription databases). Patient information was extracted from January 2010 to July 2018, for cohorts aged between 50 and 85 years. Participants: A total of 88,298,289 subjects aged between 50 and 85 years were identified. For the positive cohort, 667,288 subjects were identified who had 24 months of medical history and at least one record with AD or AD treatment. For the negative cohort, 3,670,254 patients were selected who had a similar length of medical history and who were matched to positive cohort subjects based on the prevalence rate. The scoring cohort was selected based on availability of recent medical data of 2-5 years and included 72,670,283 subjects between the ages of 50 and 85 years. Intervention (if any): None. Measurements: A list of clinically-relevant and interpretable predictors was generated and extracted from the data sets for each subject, including pharmacological treatments (NDC/product), office/specialist visits (specialty), tests and procedures (HCPCS and CPT), and diagnosis (ICD). The positive cohort was defined as patients who have AD diagnosis/AD treatment with a 3 years offset as an estimate for prodromal AD diagnosis. Supervised ML techniques were used to develop algorithms to predict the occurrence of prodromal AD cases. The sample dataset was divided randomly into a training dataset and a test dataset. The classification models were trained and executed in the PySpark framework. Training and evaluation of LogisticRegression, DecisionTreeClassifier, RandomForestClassifier, and GBTClassifier were executed using PySpark’s mllib module. The area under the precision-recall curve (AUCPR) was used to compare the results of the various models. Results: The AUCPRs are 0.426, 0.157, 0.436, and 0.440 for LogisticRegression, DecisionTreeClassifier, RandomForestClassifier, and GBTClassifier, respectively, meaning that GBTClassifier (Gradient Boosted Tree) outperforms the other three classifiers. The GBT model identified 222,721 subjects in the prodromal AD stage with 80% precision. Some 76% of identified prodromal AD patients were in the primary care setting. Conclusions: Applying the developed predictive model to 72,670,283 U.S. residents, 222,721 prodromal AD patients were identified, the majority of whom were in the primary care setting. This could drive major advances in AD research by enabling more accurate and earlier prodromal AD diagnosis at the primary care physician level , which would facilitate timely referral to expert sites for in-depth assessment and potential enrolment in clinical trials.

CITATION:
O. Uspenskaya-Cadoz ; C. Alamuri ; L. Wang ; M. Yang ; S. Khinda ; Y. Nigmatullina ; T. Cao ; N. Kayal ; M. O’Keefe ; C. Rubel (2019): Machine Learning Algorithm Helps Identify Non-Diagnosed Prodromal Alzheimer’s Disease Patients in the General Population . The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.10

Download PDFView HTML

Read more...

EDITORIAL: FAILURE AFTER FAILURE. WHAT NEXT IN AD DRUG DEVELOPMENT?

P.S. Aisen

Show summaryHide summary



CITATION:
P.S. Aisen (2019): Editorial: Failure After Failure. What Next in AD Drug Development?. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.23

Download PDFView HTML

Read more...

COMMENTARY: DEVELOPMENT OF THE BLOOD-BASED ALZHEIMER’S DISEASE LIQUID BIOPSY

H. Hampel, S. Lista, A. Vergallo, for the Alzheimer Precision Medicine Initiative (APMI)

Show summaryHide summary



CITATION:
H. Hampel ; S. Lista ; A. Vergallo ; for the Alzheimer Precision Medicine Initiative (APMI) (2019): Commentary: Development of the Blood-Based Alzheimer’s Disease Liquid Biopsy. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.22

Download PDFView HTML

Read more...

PLASMA BIOMARKERS OF AD EMERGING AS ESSENTIAL TOOLS FOR DRUG DEVELOPMENT: AN EU/US CTAD TASK FORCE REPORT

R.J. Bateman, K. Blennow, R. Doody, S. Hendrix, S. Lovestone, S. Salloway, R. Schindler, M. Weiner, H. Zetterberg, P. Aisen, B. Vellas, and the EU/US CTAD Task Force

Show summaryHide summary

There is an urgent need to develop reliable and sensitive blood-based biomarkers of Alzheimer’s disease (AD) that can be used for screening and to increase the efficiency of clinical trials. The European Union-North American Clinical Trials in Alzheimer’s Disease Task Force (EU/US CTAD Task Force) discussed the current status of blood-based AD biomarker development at its 2018 annual meeting in Barcelona, Spain. Recent improvements in technologies to assess plasma levels of amyloid beta indicate that a single sample of blood could provide an accurate estimate of brain amyloid positivity. Plasma neurofilament light protein appears to provide a good marker of neurodegeneration, although not specific for AD. Plasma tau shows some promising results but weak or no correlation with CSF tau levels, which may reflect rapid clearance of tau in the bloodstream. Blood samples analyzed using -omics and other approaches are also in development and may provide important insight into disease mechanisms as well as biomarker profiles for disease prediction. To advance these technologies, international multidisciplinary, multi-stakeholder collaboration is essential.

CITATION:
R.J. Bateman ; K. Blennow ; R. Doody ; S. Hendrix ; S. Lovestone ; S. Salloway ; R. Schindler ; M. Weiner ; H. Zetterberg ; P. Aisen ; B. Vellas ; and the EU/US CTAD Task Force (2019): Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.21

FREE ACCESS

Download PDF (174.73 Ko)View HTML

Read more...

EDITORIAL: BLOOD TESTS FOR ALZHEIMER’S DISEASE AND RELATED DISORDERS

E.M. Reiman

Show summaryHide summary

br />
CITATION:
E.M. Reiman (2019): Editorial: Blood Tests for Alzheimer’s Disease and Related Disorders. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.20

Download PDFView HTML

Read more...

COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE

E. Siemers

Show summaryHide summary



CITATION:
E. Siemers (2019): Commentary: Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.19

Download PDFView HTML

Read more...

COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE – THE NEXT STEP

F. Jessen

Show summaryHide summary



CITATION:
F. Jessen (2019): Commentary: Combination Therapy for Alzheimer’s Disease – The Next Step. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.18

Download PDFView HTML

Read more...

COMMENTARY: OPPORTUNITIES FOR COMBINATION TRIALS

C. Ballard, A. Corbett

Show summaryHide summary



CITATION:
C. Ballard ; A. Corbett (2019): Commentary: Opportunities for Combination Trials. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.17

Download PDFView HTML

Read more...

COMMENTARY: TREATING ALZHEIMER’S DISEASE : COMBINE OR FAIL ?

S. Bakchine

Show summaryHide summary



CITATION:
S. Bakchine (2019): Commentary: Treating Alzheimer’s Disease : Combine or Fail ? . The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.16

Download PDFView HTML

Read more...

COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE

S. Gauthier, J. Alam, H. Fillit, T. Iwatsubo, H. Liu-Seifert, M. Sabbagh, S. Salloway, C. Sampaio, J.R. Sims, B. Sperling, R. Sperling, K.A. Welsh-Bohmer, J. Touchon, B. Vellas, P. Aisen, and the EU/US/CTAD Task Force

Show summaryHide summary

Combination therapy is expected to play an important role for the treatment of Alzheimer’s disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer’s Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to the development of combination therapy for AD and current efforts to address these challenges. Task Force members unanimously agreed that successful treatment of AD will likely require combination therapy approaches that target multiple mechanisms and pathways. They further agreed on the need for global collaboration and sharing of data and resources to accelerate development of such approaches.

CITATION:
S. Gauthier ; J. Alam ; H. Fillit ; T. Iwatsubo ; H. Liu-Seifert ; M. Sabbagh ; S. Salloway ; C. Sampaio ; J.R. Sims ; B. Sperling ; R. Sperling ; K.A. Welsh-Bohmer ; J. Touchon ; B. Vellas ; P. Aisen ; and the EU/US/CTAD Task Force (2019): Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.12

Download PDFView HTML

Read more...

EDITORIAL: IS NOW THE TIME FOR COMBINATION THERAPIES FOR ALZHEIMER DISEASE?

J.C. Morris

Show summaryHide summary



CITATION:
J.C. Morris (2019): Editorial: Is Now the Time for Combination Therapies for Alzheimer Disease?. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.15

Download PDFView HTML

Read more...

ANTI-TAU TRIALS FOR ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCE

J. Cummings, K. Blennow, K. Johnson, M. Keeley, R.J. Bateman, J.L. Molinuevo, J. Touchon, P. Aisen, B. Vellas, and the EU/US/CTAD Task Force

Show summaryHide summary

Efforts to develop effective disease-modifying treatments for Alzheimer’s disease (AD) have mostly targeted the amyloid β (Aβ) protein; however, there has recently been increased interest in other targets including phosphorylated tau and other forms of tau. Aggregated tau appears to spread in a characteristic pattern throughout the brain and is thought to drive neurodegeneration. Both neuropathological and imaging studies indicate that tau first appears in the entorhinal cortex and then spreads to the neocortex. Anti-tau therapies currently in Phase 1 or 2 trials include passive and active immunotherapies designed to prevent aggregation, seeding, and spreading, as well as small molecules that modulate tau metabolism and function. EU/US/CTAD Task Force members support advancing the development of anti-tau therapies, which will require novel imaging agents and biomarkers, a deeper understanding of tau biology and the dynamic interaction of tau and Aβ protein, and development of multiple targets and candidate agents addressing the tauopathy of AD. Incorporating tau biomarkers in AD clinical trials will provide additional knowledge about the potential to treat AD by targeting tau.

CITATION:
J. Cummings ; K. Blennow ; K. Johnson ; M. Keeley ; R.J. Bateman ; J.L. Molinuevo ; J. Touchon ; P. Aisen ; B. Vellas ; and the EU/US/CTAD Task Force (2019): Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.14

FREE ACCESS

Download PDF (328.62 Ko)View HTML

Read more...

EDITORIAL: TAU BASED THERAPEUTICS: ALTERNATIVE APPROACHES IN THE WAR ON ALZHEIMER’S DISEASE

M. Grundman

Show summaryHide summary



CITATION:
M. Grundman (2019): Editorial: Tau Based Therapeutics: Alternative Approaches in the War on Alzheimer’s Disease. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.13

Download PDFView HTML

Read more...

ADVANCING ALZHEIMER’S DISEASE TREATMENT: LESSONS FROM CTAD 2018

B. Vellas, L.J. Bain, J. Touchon, P.S. Aisen

Show summaryHide summary

The 2018 Clinical Trials on Alzheimer’s Disease (CTAD) conference showcased recent successes and failures in trials of Alzheimer’s disease treatments. More importantly, the conference provided opportunities for investigators to share what they have learned from those studies with the goal of designing future trials with a greater likelihood of success. Data from studies of novel and non-amyloid treatment approaches were also shared, including neuroprotective and regenerative strategies and those that target neuroinflammation and synaptic function. New tools to improve the efficiency and productivity of clinical trials were described, including biomarkers and machine learning algorithms for predictive modeling.

CITATION:
B. Vellas ; L.J. Bain ; J. Touchon ; P.S. Aisen (2019): Advancing Alzheimer’s Disease Treatment: Lessons from CTAD 2018. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.11

Download PDFView HTML

Read more...

DIETARY FAT INTAKE AND COGNITIVE FUNCTION AMONG OLDER POPULATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS

G.-Y. Cao, M. Li, L. Han, F. Tayie, S.-S. Yao, Z. Huang, P. Ai, Y.-Z. Liu, Y.-H. Hu, B. Xu

Show summaryHide summary

Objective: The associations between dietary fat intake and cognitive function are inconsistent and inconclusive. This study aimed to provide a quantitative synthesis of prospective cohort studies on the relationship between dietary fat intake and cognitive function among older adults. Methods: PubMed, EMBASE, PsycINFO and Web of Science databases were searched for prospective cohort studies published in English before March 2018 reporting cognitive outcomes in relation to dietary fat intake. Four binary incident outcomes included were mild cognitive impairment (MCI), dementia, Alzheimer disease (AD) and cognitive impairment. The categories of dietary fat intake were based on fat consumption or the percentage of energy from fat consumption, including dichotomies, tertiles, quartiles and quintiles. The relative risk (RR) with the corresponding 95% confidence intervals (CIs) was pooled using a random effects model. Results: Nine studies covering a total of 23,402 participants were included. Compared with the lowest category of consumption, the highest category of saturated fat intake was associated with an increased risk of cognitive impairment (RR = 1.40; 95% CI: 1.02-1.91) and AD (RR: 1.87, 95% CI: 1.09-3.20). The total and unsaturated fat intake was not statistically associated with cognitive outcomes with significant between-study heterogeneity. Conclusion: This study reported a detrimental association between saturated fat intake and cognitive impairment and mixed results between unsaturated fat intake and selected cognitive outcomes. Given the substantial heterogeneity in the sample size and methodology used across studies, the evidence presented here should be interpreted with caution.

CITATION:
G.-Y. Cao ; M. Li ; L. Han ; F. Tayie ; S.-S. Yao ; Z. Huang ; P. Ai ; Y.-Z. Liu ; Y.-H. Hu ; B. Xu (2019): Dietary Fat Intake and Cognitive Function among Older Populations: A Systematic Review and Meta-Analysis. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.9

Download PDFView HTML

Read more...

JPAD Volume 6, N°02 - 2019

 

Editorials

IMPLICATIONS FOR BACE1 INHIBITOR CLINICAL TRIALS: ADULT CONDITIONAL BACE1 KNOCKOUT MICE EXHIBIT AXONAL ORGANIZATION DEFECTS IN THE HIPPOCAMPUS

R. Vassar

J Prev Alz Dis 2019;6(2):78-84

Show summaryHide summary

BACE1 is the rate-limiting enzyme for the production of the Aβ peptide that forms amyloid plaques in Alzheimer’s disease (AD). Small molecule inhibitors of BACE1 are being tested in clinical trials for AD, but the safety and efficacy of BACE1 inhibition has yet to be fully explored. Knockout of the Bace1 gene in the germline of mice causes multiple neurological phenotypes, suggesting that BACE1 inhibition could be toxic. However, these phenotypes could be the result of BACE1 deficiency during development rather than due to the lack of BACE1 function in the adult. To address this problem, we generated tamoxifen-inducible conditional BACE1 knockout mice in which the Bace1 gene may be deleted in the whole body of the adult at will. Importantly, the adult conditional BACE1 knockout mice largely lack phenotypes, indicating that many BACE1 functions are not required in the adult organism. However, a germline phenotype was observed after BACE1 knockout in the adult: reduced length and disorganization of the hippocampal mossy fiber infrapyramidal bundle comprised of axons of dentate gyrus granule cells. The infrapyramidal bundle abnormality correlated with reduced proteolytic processing of the neural cell adhesion protein CHL1 that is involved in axonal guidance. We conclude that BACE1 inhibition in the adult mouse brain does not lead to the phenotypes associated with BACE1 deficiency during embryonic and postnatal development. However, adult conditional BACE1 knockout mice also suggest that BACE1 inhibitor drugs may disrupt the organization of an axonal pathway in the hippocampus, an important structure for learning and memory. Here, I review the adult conditional BACE1 knockout results and consider their implications for BACE1 inhibitor clinical trials.

CITATION:
R. Vassar (2019): Implications for BACE1 Inhibitor Clinical Trials: Adult Conditional BACE1 Knockout Mice Exhibit Axonal Organization Defects in the Hippocampus. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.3

FREE ACCESS

Download PDF (873.21 Ko)View HTML

Read more...

Original Research

ASSESSMENT OF CLINICAL MEANINGFULNESS OF ENDPOINTS IN THE GENERATION PROGRAM BY THE INSIGHTS TO MODEL ALZHEIMER’S PROGRESSION IN REAL LIFE (IMAP) STUDY

A. Graf, V. Risson, A. Gustavsson, V. Bezlyak, A. Caputo, P.N. Tariot, J.B. Langbaum, C. Lopez Lopez, V. Viglietta

J Prev Alz Dis 2019;6(2):85-89

Show summaryHide summary

We are launching the Insights to Model Alzheimer’s Progression in Real Life study in parallel with the Alzheimer Prevention Initiative Generation Program. This is a 5-year, multinational, prospective, longitudinal, non-interventional cohort study that will collect data across the spectrum of Alzheimer’s disease. The primary objective is to assess the ability of the Alzheimer’s Prevention Initiative Cognitive Composite Test Score and Repeatable Battery for the Assessment of Neuropsychological Status to predict clinically meaningful outcomes such as diagnosis of mild cognitive impairment or dementia due to Alzheimer’s disease, and change in Clinical Dementia Rating – Global Score. This study is the first large-scale, prospective effort to establish the clinical meaningfulness of cognitive test scores that track longitudinal decline in preclinical Alzheimer’s disease. This study is also expected to contribute to our understanding of the relationships among outcomes in different stages of Alzheimer’s disease as well as models of individual trajectories during the course of the disease.

CITATION:
A. Graf ; V. Risson ; A. Gustavsson ; V. Bezlyak ; A. Caputo ; P.N. Tariot ; J.B. Langbaum ; C. Lopez Lopez ; V. Viglietta (2018): Assessment of Clinical Meaningfulness of Endpoints in the Generation Program by the Insights to Model Alzheimer’s Progression in Real Life (iMAP) Study. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2018.49

Download PDFView HTML

Read more...

UTILIZATION OF OBSERVATIONAL DATA AS A PROXY COHORT FOR COMPARISON PURPOSES WITH OPEN-LABEL STUDY RESULTS: AN EXAMPLE FROM ALZHEIMER’S DISEASE

C. Reed, M. Happich, J. Raskin, A. Tockhorn-Heidenreich, M. Belger

J Prev Alz Dis 2019;6(2):90-99

Show summaryHide summary

Background: Randomized placebo-controlled trials in the development of disease-modifying treatments for Alzheimer’s disease are typically of short duration (12–18 months), and health economic modeling requires extrapolation of treatment effects beyond the trial period. OBJECTIVES: To investigate whether observational data can be used to extrapolate data from open-label trials, we compared outcomes (cognition, function, behavior) over 36 months for patients with mild Alzheimer’s disease dementia in the GERAS observational study (proxy for placebo control) with those of the mild Alzheimer’s disease population on active treatment (solanezumab) in two 18-month randomized placebo-controlled trials (EXPEDITION and EXPEDITION2) and the additional 18-month open-label extension study (EXPEDITION-EXT). DESIGN & SETTING: Analysis of longitudinal data from patients with mild Alzheimer’s disease dementia in the GERAS observational study (conducted in France, Germany and the United Kingdom) and the EXPEDITION program (conducted in Europe, North America, South America, Asia and Australia). PARTICIPANTS: European and North American community-living patients, aged ≥55 years, with probable Alzheimer’s disease dementia and their caregivers. Mild Alzheimer’s disease dementia was defined as a Mini-Mental State Examination score of 20–26 in EXPEDITION and 21–26 in GERAS. INTERVENTION: Active treatment in both randomized placebo-controlled trials and the open-label extension study was intravenous solanezumab 400 mg every 4 weeks. Patients in GERAS were receiving treatment as part of standard care. MEASUREMENTS: Between-group differences for changes from baseline over 36 months in cognitive function, ability to perform activities of daily living, and behavioral and psychological symptoms of dementia were assessed using models stratified by propensity score. RESULTS: At baseline, patients and caregivers participating in GERAS were significantly older than those in the EXPEDITION studies, and the GERAS patient cohort had fewer years of education and a shorter time since diagnosis of Alzheimer’s disease. The baseline mean Mini-Mental State Examination score of the GERAS cohort was significantly higher (indicating better cognition) than that of patients receiving placebo or active treatment in the pooled EXPEDITION studies Baseline functional ability scores were significantly lower for the GERAS cohort, indicating poorer functioning. Propensity score stratification achieved a good balance in the baseline variables between GERAS and the two EXPEDITION arms. Over 18 months, least squares mean changes from baseline in outcome measures were similar in the GERAS cohort and the pooled placebo groups from the randomized controlled trials. Also, the 18-month results for the comparison between the GERAS cohort and the pooled active treatment groups from the randomized controlled trials were generally similar to those reported for the comparison with the control group in the randomized trial. Comparison of active treatment (EXPEDITION-EXT) and observational study (GERAS, as proxy control) results over 36 months of the open-label trial showed a significantly smaller decline in activities of daily living (instrumental and basic) in the active treatment group, reflecting better functioning, but no between-group differences at 36 months for cognitive function or behavioral and psychological symptoms of dementia. CONCLUSIONS: Comparing results from clinical trials and observational studies (real-world data) may be a useful methodological approach for informing long-term outcomes in Alzheimer’s disease drug development and could be used to inform health economic modeling. Further research using this methodological approach is needed.

CITATION:
C. Reed ; M. Happich ; J. Raskin ; A. Tockhorn-Heidenreich ; M. Belger (2019): Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer’s Disease. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.4

FREE ACCESS

Download PDF (1.19 Mo)View HTML

Read more...

MRI CLINICAL RATINGS AND COGNITIVE FUNCTION IN A CROSS-SECTIONAL POPULATION STUDY OF DEMENTIA: THE CACHE COUNTY MEMORY STUDY

Y.H.W. Tsui-Caldwell, T.J. Farrer, Z. McDonnell, Z. Christensen, C. Finuf, E.D. Bigler, J.T. Tschanz, M.C. Norton, K.A. Welsh-Bohmer

J Prev Alz Dis 2019;6(2):100-107

Show summaryHide summary

BACKGROUND: White matter integrity in aging populations is associated with increased risk of cognitive decline, dementia diagnosis, and mortality. Population-based data can elucidate this association. Objectives: To examine the association between white matter integrity, as measured by a clinical rating scale of hyperintensities, and mental status in older adults including advanced aging. Design: Scheltens Ratings Scale was used to qualitatively assess white matter (WM) hyperintensities in participants of the Cache County Memory Study (CCMS), an epidemiological study of Alzheimer’s disease in an exceptionally long-lived population. Further, the relation between Mini-Mental State Exam (MMSE) and WM hyperintensities were explored. Method: Participants consisted of 415 individuals with dementia and 22 healthy controls. Results: CCMS participants, including healthy controls, had high levels of WM pathology as measured by Scheltens Ratings Scale score. While age did not significantly relate to WM pathology, higher Scheltens Ratings Scale scores were associated with lower MMSE findings (correlation between -0.14 & -0.22; p < .05). Conclusions: WM pathology was common in this county-wide population sample of those ranging in age from 65 to 106. Increased WM burden was found to be significantly associated with decreased overall MMSE performance.

CITATION:
Y.H.W. Tsui-Caldwell ; T.J. Farrer ; Z. McDonnell ; Z. Christensen ; C. Finuf ; E.D. Bigler ; J.T. Tschanz ; M.C. Norton ; K.A. Welsh-Bohmer (2019): MRI Clinical Ratings and Cognitive Function in a Cross-Sectional Population Study of Dementia: The Cache County Memory Study. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.1

Download PDFView HTML

Read more...

SHIFT IN HOSPITALIZATIONS FOR ALZHEIMER’S DISEASE TO RELATED DEMENTIAS IN FRANCE BETWEEN 2007 AND 2017

M. Rochoy, E. Chazard, S. Gautier, R. Bordet

J Prev Alz Dis 2019;6(2):108-111

Show summaryHide summary

INTRODUCTION: Alzheimer’s disease (AD) is the first cause of dementia. Diagnostic criteria have evolved: proposals to revise the NINCDS–ADRDA criteria were published in 2007. Our aim was to analyze the evolution in the coding of AD in the French nationwide exhaustive hospital discharge database (PMSI) between 2007 and 2017. METHODS: We analyzed evolution of International Classification of Diseases and Related Health Problems, 10th edition (ICD-10) coding for AD and AD dementia in the PMSI database from 2008 to 2017 (285,748,938 inpatient stays). RESULTS: We observed a 44% decrease in the number of inpatient stays with a principal diagnosis of AD or AD dementia from 2007 (46,313 inpatient stays) to 2017 (25,856 inpatient stays) in France. Over the same period, we observed a 49% increase in the number of inpatient stays with a principal diagnosis of related dementias (other organic mental disorders or other degenerative disorders). Overall, the number of inpatient stays for dementia remained stable despite the increase in the total number of inpatient stays: 95,377 in 2007 (0.409% of inpatient stays) and 99,190 in 2017 (0.344%). CONCLUSION: We therefore note a shift from AD and AD dementia to other dementia diagnoses since 2007. This study suggests a more accurate use of AD related ICD-10 codes since the revised criteria in 2007.

CITATION:
M. Rochoy ; E. Chazard ; S. Gautier ; R. Bordet (2019): Shift in Hospitalizations for Alzheimer’s Disease to Related Dementias in France between 2007 and 2017. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.5

Download PDFView HTML

Read more...

Review Articles

BIOLOGICAL AND COGNITIVE MARKERS OF PRESENILIN1 E280A AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE: A COMPREHENSIVE REVIEW OF THE COLOMBIAN KINDRED

J.T. Fuller, A. Cronin-Golomb, J.R. Gatchel, D.J. Norton, E. Guzmán-Vélez, H.I.L. Jacobs, B. Hanseeuw, E. Pardilla-Delgado, A. Artola, A. Baena, Y. Bocanegra, K.S. Kosik, K. Chen, P.N. Tariot, K. Johnson, R.A. Sperling, E.M. Reiman, F. Lopera, Y.T. Quiroz

J Prev Alz Dis 2019;6(2):112-120

Show summaryHide summary

The study of individuals with autosomal dominant Alzheimer’s disease affords one of the best opportunities to characterize the biological and cognitive changes of Alzheimer’s disease that occur over the course of the preclinical and symptomatic stages. Unifying the knowledge gained from the past three decades of research in the world’s largest single-mutation autosomal dominant Alzheimer’s disease kindred — a family in Antioquia, Colombia with the E280A mutation in the Presenilin1 gene — will provide new directions for Alzheimer’s research and a framework for generalizing the findings from this cohort to the more common sporadic form of Alzheimer’s disease. As this specific mutation is virtually 100% penetrant for the development of the disease by midlife, we use a previously defined median age of onset for mild cognitive impairment for this cohort to examine the trajectory of the biological and cognitive markers of the disease as a function of the carriers’ estimated years to clinical onset. Studies from this cohort suggest that structural and functional brain abnormalities — such as cortical thinning and hyperactivation in memory networks — as well as differences in biofluid and in vivo measurements of Alzheimer’s-related pathological proteins distinguish Presenilin1 E280A mutation carriers from non-carriers as early as childhood, or approximately three decades before the median age of onset of clinical symptoms. We conclude our review with discussion on future directions for Alzheimer’s disease research, with specific emphasis on ways to design studies that compare the generalizability of research in autosomal dominant Alzheimer’s disease to the larger sporadic Alzheimer’s disease population.

CITATION:
J.T. Fuller ; A. Cronin-Golomb ; J.R. Gatchel ; D.J. Norton ; E. Guzmán-Vélez ; H.I.L. Jacobs ; B. Hanseeuw ; E. Pardilla-Delgado ; A. Artola ; A. Baena ; Y. Bocanegra ; K.S. Kosik ; K. Chen ; P.N. Tariot ; K. Johnson ; R.A. Sperling ; E.M. Reiman ; F. Lopera ; Y.T. Quiroz (2019): Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer’s Disease: A Comprehensive Review of the Colombian Kindred. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.6

Download PDFView HTML

Read more...

FACTORS ASSOCIATED WITH ALZHEIMER’S DISEASE: AN OVERVIEW OF REVIEWS

M. Rochoy, V. Rivas, E. Chazard, E. Decarpentry, G. Saudemont, P.-A. Hazard, F. Puisieux, S. Gautier, R. Bordet

J Prev Alz Dis 2019;6(2):121-134

Show summaryHide summary

Alzheimer’s disease (AD) is a frequent pathology, with a poor prognosis, for which no curative treatment is available in 2018. AD prevention is an important issue, and is an important research topic. In this manuscript, we have synthesized the literature reviews and meta-analyses relating to modifiable risk factors associated with AD. Smoking, diabetes, high blood pressure, obesity, hypercholesterolemia, physical inactivity, depression, head trauma, heart failure, bleeding and ischemic strokes, sleep apnea syndrome appeared to be associated with an increased risk of AD. In addition to these well-known associations, we highlight here the existence of associated factors less described: hyperhomocysteinemia, hearing loss, essential tremor, occupational exposure to magnetic fields. On the contrary, some oral antidiabetic drugs, education and intellectual activity, a Mediterranean-type diet or using Healthy Diet Indicator, consumption of unsaturated fatty acids seemed to have a protective effect. Better knowledge of risk factors for AD allows for better identification of patients at risk. This may contribute to the emergence of prevention policies to delay or prevent the onset of AD.

CITATION:
M. Rochoy ; V. Rivas ; E. Chazard ; E. Decarpentry ; G. Saudemont ; P.-A. Hazard ; F. Puisieux ; S. Gautier ; R. Bordet (2019): Factors Associated with Alzheimer’s Disease: An Overview of Reviews. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.7

Download PDFView HTML

Read more...

Brief Report

IMPLEMENTING A MEMORY CLINIC MODEL TO FACILITATE RECRUITMENT INTO EARLY PHASE CLINICAL TRIALS FOR MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE

L. Park, C. Kouhanim, S. Lee, Z. Mendoza, K. Patrick, L. Gertsik, C. Aguilar, D. Gullaba, S. Semenova, S. Jhee

J Prev Alz Dis 2019;6(2):135-138

Show summaryHide summary

Background: The recruitment challenges for MCI and AD subjects into clinical trials are well known, and this is particularly true for early phase studies. Currently, only 10-20% of all patients who are referred for research from the community are trial eligible (Grill and Karlawish, 2011). Due to the limited and specific study objectives in early phase study designs, these rates drop to approximately one patient every two months. Barriers to research recruitment are multi-factorial, involving patient centered factors, issues related to caregiver/study partner participation, and aspects related to the involvement of their treating physicians. To address this challenge, we implemented a Memory Clinic within PAREXEL’s Early Phase Clinical Pharmacology Unit. Our objective was to significantly facilitate recruitment into AD clinical trials by providing resources and education to patients, their treating physicians, and caregivers in the community. Method: The Clinic’s primary goals were to increase research visibility and partnerships with local organizations and referring physicians. Members of the research team co-sponsored community outreach events with local organizations, thereby increasing awareness about the services of this memory clinic. Secondly, physician outreach was expanded to include those who were not previously amenable to clinical trial referrals. Finally, Memory Clinic patients were given clinical evaluations, free of charge and the results were discussed with the patients and their caregivers. If the patients were interested in hearing more about possible research opportunities, they were referred to the early phase unit for a screening visit. Results: We found that new referrals for research participation significantly increased as a result of this new paradigm. In 2016, 12 patients diagnosed with MCI or AD per protocol, were referred to a research study and 3 were randomized. In 2017, 98 patients were referred and 16 were enrolled In addition, our referral network increased with 30 physicians over a 20 mile radius. Collaborations with national non-profit organizations also increased, thereby increasing public awareness about the importance of research participation in the development of new treatments for Alzheimer’s Disease. Conclusions: In summary, community engagement and providing referring physicians with a clinical service improved recruitment significantly for our phase 1 unit. Resource education, staff training, and dedicated medical professionals can significantly improve awareness about clinical research participation and provide additional participants over and above traditional recruitment methods and trial registry enrollment in a large urban area.

CITATION:
L. Park ; C. Kouhanim ; S. Lee ; Z. Mendoza ; K. Patrick ; L. Gertsik ; C. Aguilar ; D. Gullaba ; S. Semenova ; S. Jhee (2019): Implementing a Memory Clinic Model to facilitate recruitment into early phase clinical trials for Mild Cognitive Impairment and Alzheimer’s Disease. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.8

Download PDFView HTML

Read more...

CROSS-SECTIONAL CHARACTERIZATION OF ALBUMIN GLYCATION STATE IN CEREBROSPINAL FLUID AND PLASMA FROM ALZHEIMER’S DISEASE PATIENTS

M. Costa, A. Mestre, R. Horrillo, A. M. Ortiz, A. Pérez, A. Ruiz, M. Boada, S. Grancha

J Prev Alz Dis 2019;6(2):139-143

Show summaryHide summary

We determined albumin post-translational modifications (PTMs) by mass spectrometry (MS) in plasma and cerebrospinal fluid (CSF) from 31 Alzheimer’s disease (AD) patients (with 27 samples of paired plasma-CSF from the same patients). Results were cross-sectionally compared with healthy controls. For percentage of relative intensity of glycated isoforms, plasma albumin was globally more glycated in AD patients than in healthy controls (P<0.01). MS results in plasma were confirmed by a quantitative enzymatic assay (Lucica GA-L) for albumin early-glycation detection. In CSF there were no global glycation differences detected by MS, although a different pattern of glycated isoforms was observed. Oxidized+glycated and cysteinylated+glycated isoforms were increased in both plasma and CSF of AD patients in comparison with healthy controls (P<0.001). Furthermore, AD patients showed higher glycation in plasma than in CSF (P<0.01). Our data support the role of glycation and oxidative stress in AD.

CITATION:
M. Costa ; A. Mestre ; R. Horrillo ; A. M. Ortiz ; A. Pérez ; A. Ruiz ; M. Boada ; S. Grancha (2018): Cross-Sectional Characterization of Albumin Glycation State in Cerebrospinal Fluid and Plasma from Alzheimer’s Disease Patients. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2018.48

Download PDFView HTML

Read more...

Short Communication

REPORT FROM THE FIRST CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) ASIA-CHINA 2018 : BRINGING TOGETHER GLOBAL LEADERS

J.K. Chhetri, P. Chan, B. Vellas, J. Touchon, S. Gauthier

J Prev Alz Dis 2019;6(2):144-147

Show summaryHide summary

Population of older adults in Asia, and particularly in China is increasing rapidly. Older population are at increased risk of Alzheimer’s disease (AD) and other dementias. Soon, the Chinese population with AD will represent almost half of the world’s AD population. There is a desperate need of disease modifying therapies to delay or slow the progression of AD, to tackle this emerging healthcare emergency. In this context, the first CTAD Asia-China conference was held in China to bring together Western and Asian leaders in AD. This meeting focused largely on how to develop successful trials in China, utilizing past experiences from the West.

CITATION:
J.K. Chhetri ; P. Chan ; B. Vellas ; J. Touchon ; S. Gauthier (2019): Report from the First Clinical Trials on Alzheimer’s Disease (CTAD) Asia-China 2018 : Bringing together Global Leaders. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2019.2

Download PDFView HTML

Read more...